Comparison between sirolimus- and paclitaxel-eluting stents for the treatment of chronic total occlusions

Jae Sik Jang, Myeongki Hong, Cheol Whan Lee, Duk Woo Park, Bong Ki Lee, Young Hak Kim, Ki Hoon Han, Jae Joong Kim, Seong Wook Park, Seung Jung Park

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

OBJECTIVES: This study evaluated the clinical and angiographic effectiveness of sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES) implantation for chronic total occlusion (CTO) lesions. BACKGROUND: It has not been known which drug-eluting stent, SES vs. PES, is superior for the treatment of CTO lesions. METHODS: This study comprises 107 CTO lesions which were successfully treated with SES implantation and 29 CTO lesions with PES implantation. Six-month angiographic restenosis rates and major adverse cardiac events (MACE) including death, nonfatal myocardial infarction and target lesion revascularization were compared between the two groups. RESULTS: Baseline clinical characteristics were similar between the two groups. The procedural success rate was 98.1% in the SES group and 100% in the PES group. There was 1 sudden death due to in-hospital acute thrombosis in the PES group. There were no significant differences in baseline angiographic measures between both groups, except larger postprocedural minimal luminal diameter and acute gain in the PES group. At 6-month angiographic follow up, the restenosis rate was significantly higher in the PES group (28.6% vs. 9.4%; p = 0.020). Similarly, the late loss was significantly higher in the PES group (0.8 ± 0.8 mm vs. 0.4 ± 0.8 mm; p = 0.025). At one-year follow up, the MACE-free survival rate was significantly higher in the SES group (95.8% vs. 85.8%; p = 0.049). CONCLUSIONS: The implantation of SES in the treatment of CTO lesions showed more favorable results regarding restenosis and clinical outcomes compared with PES implantation.

Original languageEnglish
Pages (from-to)205-208
Number of pages4
JournalJournal of Invasive Cardiology
Volume18
Issue number5
Publication statusPublished - 2006 May 1

Fingerprint

Sirolimus
Paclitaxel
Stents
Drug-Eluting Stents
Sudden Death
Disease-Free Survival
Thrombosis

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Jang, J. S., Hong, M., Lee, C. W., Park, D. W., Lee, B. K., Kim, Y. H., ... Park, S. J. (2006). Comparison between sirolimus- and paclitaxel-eluting stents for the treatment of chronic total occlusions. Journal of Invasive Cardiology, 18(5), 205-208.
Jang, Jae Sik ; Hong, Myeongki ; Lee, Cheol Whan ; Park, Duk Woo ; Lee, Bong Ki ; Kim, Young Hak ; Han, Ki Hoon ; Kim, Jae Joong ; Park, Seong Wook ; Park, Seung Jung. / Comparison between sirolimus- and paclitaxel-eluting stents for the treatment of chronic total occlusions. In: Journal of Invasive Cardiology. 2006 ; Vol. 18, No. 5. pp. 205-208.
@article{5237b2d92f7a4876a73678034b3cb0e5,
title = "Comparison between sirolimus- and paclitaxel-eluting stents for the treatment of chronic total occlusions",
abstract = "OBJECTIVES: This study evaluated the clinical and angiographic effectiveness of sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES) implantation for chronic total occlusion (CTO) lesions. BACKGROUND: It has not been known which drug-eluting stent, SES vs. PES, is superior for the treatment of CTO lesions. METHODS: This study comprises 107 CTO lesions which were successfully treated with SES implantation and 29 CTO lesions with PES implantation. Six-month angiographic restenosis rates and major adverse cardiac events (MACE) including death, nonfatal myocardial infarction and target lesion revascularization were compared between the two groups. RESULTS: Baseline clinical characteristics were similar between the two groups. The procedural success rate was 98.1{\%} in the SES group and 100{\%} in the PES group. There was 1 sudden death due to in-hospital acute thrombosis in the PES group. There were no significant differences in baseline angiographic measures between both groups, except larger postprocedural minimal luminal diameter and acute gain in the PES group. At 6-month angiographic follow up, the restenosis rate was significantly higher in the PES group (28.6{\%} vs. 9.4{\%}; p = 0.020). Similarly, the late loss was significantly higher in the PES group (0.8 ± 0.8 mm vs. 0.4 ± 0.8 mm; p = 0.025). At one-year follow up, the MACE-free survival rate was significantly higher in the SES group (95.8{\%} vs. 85.8{\%}; p = 0.049). CONCLUSIONS: The implantation of SES in the treatment of CTO lesions showed more favorable results regarding restenosis and clinical outcomes compared with PES implantation.",
author = "Jang, {Jae Sik} and Myeongki Hong and Lee, {Cheol Whan} and Park, {Duk Woo} and Lee, {Bong Ki} and Kim, {Young Hak} and Han, {Ki Hoon} and Kim, {Jae Joong} and Park, {Seong Wook} and Park, {Seung Jung}",
year = "2006",
month = "5",
day = "1",
language = "English",
volume = "18",
pages = "205--208",
journal = "Journal of Invasive Cardiology",
issn = "1042-3931",
publisher = "HMP Communications",
number = "5",

}

Jang, JS, Hong, M, Lee, CW, Park, DW, Lee, BK, Kim, YH, Han, KH, Kim, JJ, Park, SW & Park, SJ 2006, 'Comparison between sirolimus- and paclitaxel-eluting stents for the treatment of chronic total occlusions', Journal of Invasive Cardiology, vol. 18, no. 5, pp. 205-208.

Comparison between sirolimus- and paclitaxel-eluting stents for the treatment of chronic total occlusions. / Jang, Jae Sik; Hong, Myeongki; Lee, Cheol Whan; Park, Duk Woo; Lee, Bong Ki; Kim, Young Hak; Han, Ki Hoon; Kim, Jae Joong; Park, Seong Wook; Park, Seung Jung.

In: Journal of Invasive Cardiology, Vol. 18, No. 5, 01.05.2006, p. 205-208.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison between sirolimus- and paclitaxel-eluting stents for the treatment of chronic total occlusions

AU - Jang, Jae Sik

AU - Hong, Myeongki

AU - Lee, Cheol Whan

AU - Park, Duk Woo

AU - Lee, Bong Ki

AU - Kim, Young Hak

AU - Han, Ki Hoon

AU - Kim, Jae Joong

AU - Park, Seong Wook

AU - Park, Seung Jung

PY - 2006/5/1

Y1 - 2006/5/1

N2 - OBJECTIVES: This study evaluated the clinical and angiographic effectiveness of sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES) implantation for chronic total occlusion (CTO) lesions. BACKGROUND: It has not been known which drug-eluting stent, SES vs. PES, is superior for the treatment of CTO lesions. METHODS: This study comprises 107 CTO lesions which were successfully treated with SES implantation and 29 CTO lesions with PES implantation. Six-month angiographic restenosis rates and major adverse cardiac events (MACE) including death, nonfatal myocardial infarction and target lesion revascularization were compared between the two groups. RESULTS: Baseline clinical characteristics were similar between the two groups. The procedural success rate was 98.1% in the SES group and 100% in the PES group. There was 1 sudden death due to in-hospital acute thrombosis in the PES group. There were no significant differences in baseline angiographic measures between both groups, except larger postprocedural minimal luminal diameter and acute gain in the PES group. At 6-month angiographic follow up, the restenosis rate was significantly higher in the PES group (28.6% vs. 9.4%; p = 0.020). Similarly, the late loss was significantly higher in the PES group (0.8 ± 0.8 mm vs. 0.4 ± 0.8 mm; p = 0.025). At one-year follow up, the MACE-free survival rate was significantly higher in the SES group (95.8% vs. 85.8%; p = 0.049). CONCLUSIONS: The implantation of SES in the treatment of CTO lesions showed more favorable results regarding restenosis and clinical outcomes compared with PES implantation.

AB - OBJECTIVES: This study evaluated the clinical and angiographic effectiveness of sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES) implantation for chronic total occlusion (CTO) lesions. BACKGROUND: It has not been known which drug-eluting stent, SES vs. PES, is superior for the treatment of CTO lesions. METHODS: This study comprises 107 CTO lesions which were successfully treated with SES implantation and 29 CTO lesions with PES implantation. Six-month angiographic restenosis rates and major adverse cardiac events (MACE) including death, nonfatal myocardial infarction and target lesion revascularization were compared between the two groups. RESULTS: Baseline clinical characteristics were similar between the two groups. The procedural success rate was 98.1% in the SES group and 100% in the PES group. There was 1 sudden death due to in-hospital acute thrombosis in the PES group. There were no significant differences in baseline angiographic measures between both groups, except larger postprocedural minimal luminal diameter and acute gain in the PES group. At 6-month angiographic follow up, the restenosis rate was significantly higher in the PES group (28.6% vs. 9.4%; p = 0.020). Similarly, the late loss was significantly higher in the PES group (0.8 ± 0.8 mm vs. 0.4 ± 0.8 mm; p = 0.025). At one-year follow up, the MACE-free survival rate was significantly higher in the SES group (95.8% vs. 85.8%; p = 0.049). CONCLUSIONS: The implantation of SES in the treatment of CTO lesions showed more favorable results regarding restenosis and clinical outcomes compared with PES implantation.

UR - http://www.scopus.com/inward/record.url?scp=33745001772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745001772&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 205

EP - 208

JO - Journal of Invasive Cardiology

JF - Journal of Invasive Cardiology

SN - 1042-3931

IS - 5

ER -